Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyWPS Health Insurance Ankle Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentWPS Health InsurancePolicy 250-0009

    Ankle Arthroplasty, Total Medical Guideline

    Customize your policy alerts

    Sign up for WPS Health Insurance Policy 250-0009 alerts

    Get alerted when Policy 250-0009 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs coverage of total ankle arthroplasty, including primary replacement and revision of failed total ankle prostheses. Coverage depends on the member's benefit plan, medical necessity criteria, FDA-approved implant use, required documentation, and applicable exclusions and limitations.

    Policy Summary
    PayerWPS Health Insurance
    PolicyAnkle Arthroplasty, Total Medical Guideline
    Policy CodePolicy 250-0009
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewSep 10, 2026
    Next Review DateN/A
    Key ActionReview the member's health plan and endorsements for applicable prior-authorization, exclusion, or benefit requirements before requesting the service.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 weeksRequired medication trial
    14Exclusion conditions
    FDA-approvedRequired implant status
    2Primary criteria required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Total Ankle Arthroplasty Coverage Criteria

    Primary total ankle arthroplasty

    Primary total ankle arthroplasty is medically necessary when all criteria are met.

    • Clinical indication: The individual has arthritis of the ankle with moderate to severe pain and loss of function or mobility of the ankle joint to be treated.Moderate to severe pain plus loss of function or mobility
    • Conservative medication trial: The individual has completed a two-week trial of non-steroidal anti-inflammatory drugs, or other pain medication if NSAIDs are not tolerated or indicated.Two weeks

      An alternative pain medication may be used when NSAIDs are not tolerated or indicated.

    Revision total ankle arthroplasty

    Revision total ankle arthroplasty is medically necessary when all criteria are met.

    • Failed prosthesis: The individual has a failed total ankle prosthesis.

      Examples include loosening, malposition, periprosthetic fracture, or infection.

    • Original implant status: The original total ankle replacement was an FDA-approved implant.FDA approved

    Experimental, investigational, and unproven conditions

    Total ankle arthroplasty is experimental, investigational, and unproven to affect health outcomes when any one of the following is present.

    Exclusion conditions

    • Active or prior deep infection in the ankle joint or adjacent bones.
    • Avascular necrosis of the talus.
    • Charcot joint of the affected ankle.
    • Hindfoot or forefoot malalignment preventing a plantigrade foot.
    • Insufficient ligament support that cannot be corrected with soft-tissue stabilization.

    Non-FDA-approved prosthetic devices are excluded from coverage. The surgeon is responsible for selecting a United States Food and Drug Administration (FDA)-approved prosthetic implant with proven safety and efficacy that is appropriate for the individual.

    Intraoperative surgical navigation and robotic assistance used for ankle arthroplasty are considered integral to the surgical procedure and are not separately covered services.

    Ankle viscosupplementation injections, including Hyaluronan, Hyalgan, hylan-GF-20, and Synvisc, are considered experimental, investigational, and unproven to affect health outcomes. Synvisc is not FDA approved for use in the ankle.

    A request for a condition or diagnosis listed in the indications but not meeting the stated coverage criteria is considered not medically necessary.

    Zilretta (triamcinolone acetonide extended-release injectable suspension) injections are considered not medically necessary.

    Requirements for Submission and Coverage Review

    Prior Authorization

    Check Plan-Specific Requirements

    Review the member’s health plan and any endorsements before submission. Confirm whether prior authorization, exclusions, benefit limitations, and other plan-specific requirements apply.

    Documentation Required

    Standard Written Order Required

    Submit a Standard Written Order prescribed by a qualified healthcare provider concerning the member’s diagnosis.

    Documentation Required

    Medical Records and Medical Necessity

    Submit medical records supporting the diagnosis and medical necessity, including physical findings, pain, functional or mobility limitations, conservative treatment history, and history of ankle injury or surgery. Include documentation of continued need or use, if applicable.

    Billing Rule

    Correct Coding Required

    Use correct coding for the requested item or service and comply with all applicable coding guidelines.

    Denial Risk

    Non-FDA-Approved Implant Not Covered

    WPS does not cover a non-FDA-approved prosthetic implant. The surgeon is responsible for selecting a United States Food and Drug Administration (FDA)-approved implant with proven safety and efficacy that is appropriate for the patient.

    Denial Risk

    Primary Coverage Criteria Must Be Met

    Primary total ankle arthroplasty is medically necessary only for a skeletally mature individual with ankle arthritis, moderate to severe pain, and loss of ankle function or mobility who has completed a two-week NSAID trial, or another pain medication trial when NSAIDs are not tolerated or indicated. Failure to satisfy both criteria creates a not-medically-necessary denial risk.

    Denial Risk

    Revision Criteria Must Be Met

    Revision total ankle arthroplasty is medically necessary only for a failed total ankle prosthesis, such as loosening, malposition, periprosthetic fracture, or infection, when the original replacement was an FDA-approved implant. Missing documented prosthesis failure or FDA-approved implant status creates a denial risk.

    Denial Risk

    Listed Exclusion Conditions Trigger Unproven Status

    Total ankle arthroplasty is considered experimental, investigational, and unproven to affect health outcomes when any listed exclusion condition is present, or when the requested condition is outside the indications of coverage.

    • Active or prior deep infection in the ankle joint or adjacent bones
    • Avascular necrosis of the talus
    • Charcot joint of the affected ankle
    • Hindfoot or forefoot malalignment preventing a plantigrade foot
    • Insufficient ligament support that cannot be corrected with soft-tissue stabilization
    • Peripheral arterial disease affecting the lower extremity targeted for surgery
    • Neuromuscular disease causing lack of normal muscle function about the affected ankle
    • Poor skin or soft-tissue quality at the surgical site
    • Prior surgery or injury adversely affecting ankle bone quality
    • Psychiatric problems hindering adequate perioperative cooperation
    • Severe osteoporosis, osteopenia, or other poor bone-quality condition that may result in inadequate bony fixation
    • Significant malalignment of the knee joint
    • Skeletal immaturity
    • Subtalar arthroereisis (subtalar joint implantation)
    Billing Rule

    Navigation and Robotic Assistance Are Integral

    Intraoperative surgical navigation and robotic assistance for ankle arthroplasty are integral to the surgical procedure and should not be treated as separate covered services.

    Denial Risk

    Injection Limitations

    Ankle viscosupplementation injections, including Hyaluronan, Hyalgan, hylan-GF-20, and Synvisc, are considered experimental, investigational, and unproven to affect health outcomes. Synvisc is not FDA-approved for use in the ankle, and Zilretta (triamcinolone acetonide extended-release injectable suspension) injections are considered not medically necessary.

    About Total Ankle Arthroplasty

    Total ankle arthroplasty (TAA), also called total ankle replacement (TAR), is a surgical procedure that replaces an arthritic ankle joint with a man-made prosthetic implant. This guideline addresses primary replacement in skeletally mature individuals with symptomatic, function-limiting ankle arthritis and revision of failed total ankle prostheses. Coverage is subject to the applicable medical-necessity criteria, use of an FDA-approved implant, documentation requirements, benefit-plan provisions, and stated exclusions and limitations.

    Key Terms

    Total Ankle Arthroplasty (TAA)
    ProcedureA surgical procedure for arthritis in which the ankle joint is replaced with a man-made prosthetic implant.
    Implant requirementThe prosthetic implant must be approved by the United States Food and Drug Administration (FDA).
    Total Ankle Replacement (TAR)
    Alternate nameTotal Ankle Replacement (TAR) is another name for total ankle arthroplasty.
    Policy Summary
    PayerWPS Health Insurance
    PolicyAnkle Arthroplasty, Total Medical Guideline
    Policy CodePolicy 250-0009
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewSep 10, 2026
    Next Review DateN/A
    Key ActionReview the member's health plan and endorsements for applicable prior-authorization, exclusion, or benefit requirements before requesting the service.
    SourceLink
    On This Page
    Total Ankle Arthroplasty Coverage CriteriaRequirements for Submission and Coverage ReviewAbout Total Ankle ArthroplastyKey Terms
    Peripheral arterial disease affecting the lower extremity targeted for surgery.
  1. Neuromuscular disease resulting in lack of normal muscle function about the affected ankle.
  2. Poor skin or soft-tissue quality: Poor skin and soft-tissue quality about the surgical site.
  3. Adverse prior surgery or injury: Prior surgery or injury that has adversely affected ankle bone quality.
  4. Psychiatric problem or problems that hinder adequate cooperation during the perioperative period.
  5. Poor bone quality: Severe osteoporosis, osteopenia, or another condition resulting in poor bone quality that may result in inadequate bony fixation.
  6. Knee malalignment: Significant malalignment of the knee joint.
  7. Skeletal immaturity: Skeletal maturity has not yet been reached.Skeletal maturity required
  8. Subtalar arthroereisis or subtalar joint implantation.